How Immune-related Response Criteria Is Changing Immunotherapy Treatments

Immune-related response criteria (irRC) is an essential tool for every investigator conducting immunotherapy trials. Improper evaluation of response data can signal a lack of efficacy and cause sponsors to prematurely end a study … when the immunotherapy treatment is actually working.

Since irRC has become an important efficacy criteria for evaluating treatment response, everyone involved in the design and conduct of cancer immunotherapy trials should understand the fundamentals of irRC and its application.

Join our team of oncology experts on May 14, 2015 at 1pm EST to learn:

  • How to use the irRC to prevent prematurely ending the trial due to lack of efficacy
  • Practical use of irRC with examples
  • The future direction of the irRC
  • Radiology issues pertinent to irRC

This valuable session can help you understand the true value of irRC and how to use it in your study.

Seats Are Limited. Save Your Seat Now!

The webinar content is designed for CMOs, VPs of Clinical Development, and others designing and managing immunotherapy studies in oncology.

DATE: May 14, 2015

Register Now

Speakers include:

John Grous, MD, Vice President, Medical Affairs

Dr. Grous is a board-certified medical oncologist with extensive experience serving as medical monitor for numerous cancer immunotherapy trials.  He has served in the biotech and pharmaceutical industry from medical director to vice-president with several companies for over sixteen years.

David Browning, Vice President, Clinical Operations

David Browning has over 20 years of oncology clinical research experience leading Phase I – III clinical studies in the US, having managed the daily activities of over 200 clinical trials including many immunotherapy studies.

We hope to see you on the 14th!